GH Research GHRS
NASDAQ GHRS
$28.01 +0.09 (+0.32%)
As of: Sep 4, 2026 · 2:31 PM EDT

GH Research (GHRS) Income towards Parent Company (2020 - 2026)

GH Research (GHRS) posted quarterly Income towards Parent Company of -$14.1 million for Q4 2025, down 60.61% year-over-year from -$35.9 million in Q4 2024, and down 0.83% quarter-over-quarter from -$14.0 million in Q3 2025.

Analysis

GH Research (GHRS) Income towards Parent Company (2020 - 2026) Analysis & Trends

GH Research's Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$14.1 million for Q4 2025.

  • In Q4 2025, Income towards Parent Company fell 60.61% year-over-year to -$14.1 million; the TTM figure through Dec 2025 stood at -$48.3 million (down 23.86% YoY), while the FY2025 annual figure was -$48.3 million, down 23.86% from the prior year.
  • Income towards Parent Company for Q4 2025 stood at -$14.1 million, down from -$14.0 million in the prior quarter.
  • The five-year high for Income towards Parent Company was $334000.0 in Q2 2022, with the low at -$16.6 million in Q4 2022.
  • The 5-year median for Income towards Parent Company is -$8.3 million (2023), against an average of -$7.7 million.
  • The sharpest annual moves came in 2021 and 2022: Income towards Parent Company slumped 2961.67% in 2021, then surged 115.72% in 2022.
  • GH Research's Income towards Parent Company stood at -$4.1 million in 2021, then slumped by 305.43% to -$16.6 million in 2022, then jumped by 32.04% to -$11.3 million in 2023, then advanced by 21.91% to -$8.8 million in 2024, then plunged by 60.61% to -$14.1 million in 2025.
  • Business Quant data shows GHRS's Income towards Parent Company at -$14.1 million in Q4 2025, -$14.0 million in Q3 2025, and -$9.3 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn -
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn -
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn
10 GH Research 1.71 Bn 1.35 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -15.15 Mn
Mar 31, 2026 -18.97 Mn
Dec 31, 2025 -14.14 Mn
Sep 30, 2025 -14.02 Mn
Jun 30, 2025 -9.29 Mn
Mar 31, 2025 -10.81 Mn
Dec 31, 2024 -8.80 Mn
Sep 30, 2024 -12.11 Mn
Jun 30, 2024 -10.38 Mn
Mar 31, 2024 -7.67 Mn
Dec 31, 2023 -11.27 Mn
Sep 30, 2023 -5.65 Mn
Jun 30, 2023 -7.73 Mn
Mar 31, 2023 -10.94 Mn
Dec 31, 2022 -16.59 Mn
Sep 30, 2022 -441,000.00
Jun 30, 2022 334,000.00
Mar 31, 2022 -5.76 Mn
Dec 31, 2021 -4.09 Mn
Sep 30, 2021 -1.84 Mn